Introduction: The Challenge of Heart Failure

Heart failure (HF) affects over 64 million people worldwide, with prevalence rising as populations age. Despite advances in pharmacotherapy and device therapy, five‑year mortality remains near 50%, highlighting an urgent need for better tools to understand, predict, and treat the condition. The heart’s function is the product of intricate interactions between electrical activation, mechanical contraction, and hemodynamic loading. Traditional diagnostic approaches—echocardiography, biomarkers, and clinical scores—provide snapshots but often miss the dynamic, nonlinear nature of the failing heart. Physiological modeling of the cardiac cycle offers a powerful alternative: it reproduces the heart’s behavior in silico, enabling clinicians and researchers to explore mechanisms, test interventions, and personalize care. By simulating the entire cycle from electrical depolarization to ventricular ejection, models can capture the subtle derangements that drive HF progression and treatment response. This article reviews the state of physiological cardiac modeling, its applications to heart failure management, and the path toward clinical adoption.

Understanding the Cardiac Cycle in Health and Disease

The cardiac cycle comprises two main phases: systole and diastole. During systole, the ventricles contract, ejecting blood into the aorta and pulmonary artery. Diastole follows as the myocardium relaxes and the chambers refill. In heart failure, one or both phases become impaired. HF with reduced ejection fraction (HFrEF) features weakened systolic contraction, whereas HF with preserved ejection fraction (HFpEF) exhibits diastolic stiffness and impaired relaxation. A comprehensive model must account for both phases and their coupling.

Phases of the Cardiac Cycle

Detailed understanding begins with the four phases:

  • Ventricular filling (diastole): rapid early filling, diastasis, and atrial contraction.
  • Isovolumetric contraction: all valves closed, pressure rises sharply.
  • Ejection: semilunar valves open, blood is expelled.
  • Isovolumetric relaxation: pressure falls, mitral valve remains closed.

In HF, these transitions become abnormal. For example, in HFpEF, the left ventricular pressure‑volume loop shifts upward and leftward, reflecting increased stiffness. Models that simulate pressure‑volume relationships can reproduce these shifts and help identify the dominant mechanism in individual patients.

The Value of Simulation

Why model a process we can measure with catheters and imaging? Because models can answer “what if” questions that are difficult or impossible to test in patients. For instance, how would a 10% reduction in systemic vascular resistance affect end‑diastolic volume in a specific patient with mitral regurgitation? Models allow virtual experimentation without risk. They also integrate disparate data—ECG, blood pressure, imaging—into a coherent picture of whole‑heart function. This integrative view is especially valuable in heart failure, where multiple systems (neurohormonal, renal, vascular) conspire to worsen function.

Physiological Modeling Techniques for the Cardiac Cycle

Cardiac modeling spans several scales and methodologies. The choice of technique depends on the question being asked: some models focus on organ‑level hemodynamics, others on cellular electrophysiology, and still others on 3D mechanics. Below are the major categories.

Lumped Parameter Models (0‑D Models)

These models represent the heart and circulation using electrical analogies: resistors, capacitors, and inductors simulate vascular resistance, compliance, and inertia. Each cardiac chamber is modeled as a time‑varying elastance—a mathematical description of chamber stiffness over the cycle. Lumped models are computationally inexpensive and ideal for studying global hemodynamics, such as the effect of vasodilators or beta‑blockers on cardiac output. They can run in real time and be coupled to closed‑loop models of the entire circulation, including baroreflex regulation. A well‑known example is the CircAdapt model, which adapts to chronic changes in preload and afterload. For heart failure, lumped models can simulate how a progressive increase in left ventricular stiffness shifts the pressure‑volume loop and eventually reduces stroke volume.

Key Lumped Parameter Models

  • Windkessel models (two‑element, three‑element, four‑element) for arterial afterload.
  • Time‑varying elastance models (e.g., Sunagawa‑Sagawa model) for ventricular function.
  • Closed‑loop circulatory models that include both heart and vascular system, often used for studying autonomic control in HF.

Electromechanical Models (1‑D to 3‑D)

These models couple electrical propagation (action potentials) with tissue mechanics. The heart’s electrical activation sequence—from the sinoatrial node through the Purkinje network to the ventricles—is simulated using the bidomain or monodomain equations. The resulting electrical activation triggers myocyte contraction, described by Hill‑type or Huxley‑type cross‑bridge models. At the organ scale, finite element methods solve for deformation, stress, and strain. Examples include the Living Heart Project (Dassault Systèmes) and models developed at the University of Auckland. Such models can simulate dyssynchrony in left bundle branch block and predict the optimal pacing site for cardiac resynchronization therapy (CRT). They also capture the mechanical consequences of scar tissue, fibrosis, and hypertrophy—all hallmarks of the failing heart.

Applications of 3‑D Electromechanical Models in HF

  • Predicting the hemodynamic response to CRT lead placement.
  • Simulating the effect of myocardial infarction scar on ventricular twist and torsion.
  • Evaluating drug effects on contractility and conduction velocity.

Hemodynamic Models

Hemodynamic models focus explicitly on blood flow and pressure, often using computational fluid dynamics (CFD). The geometry of the left ventricle, valves, and great vessels can be derived from MRI or CT scans. CFD simulations reveal flow patterns, shear stress on the endocardium, and energy losses across stenotic valves. In heart failure, CFD can assess the severity of functional mitral regurgitation or quantify the hemodynamic benefit of a ventricular assist device (VAD). Low‑order models (1‑D) of the arterial tree can also be used to estimate wave reflections and aortic stiffness, which are elevated in HFpEF.

Multi‑scale Models

The most ambitious approach integrates models from the molecular and cellular levels up to the organ and systemic levels. A multi‑scale model might include:

  • Cellular models (e.g., the Luo‑Rudy or O’Hara‑Rudy models of the ventricular action potential) that incorporate ion channels, calcium handling, and myofilament dynamics.
  • Tissue models that account for gap junction coupling and fiber orientation.
  • Organ models using finite elements with realistic geometry.
  • Systemic models representing the vasculature and neurohormonal feedback.

Such comprehensive models are computationally demanding but can simulate the effects of a genetic mutation in a single ion channel on global ejection fraction—a feat impossible with simpler approaches. For heart failure, multi‑scale models have been used to explore the role of calcium cycling abnormalities (e.g., reduced SERCA activity) in causing both systolic and diastolic dysfunction.

Applications in Heart Failure Management

The ultimate goal of cardiac modeling is to improve patient outcomes. While models have been used in research for decades, clinical translation is accelerating, driven by advances in computing and data acquisition. Below are key areas where physiological modeling directly impacts heart failure management.

Personalizing Pharmacotherapy

Drug response varies widely among heart failure patients. Beta‑blockers, ACE inhibitors, and newer agents such as sacubitril‑valsartan have different effects on heart rate, contractility, and vascular tone. Lumped parameter models can be calibrated to a patient’s baseline hemodynamics (using noninvasive data like blood pressure, heart rate, and echocardiographic volumes) and then used to predict the effect of a given drug. For example, a model might show that a particular beta‑blocker reduces heart rate too much in a patient with low baseline cardiac output, suggesting the need for a lower dose or a different agent. Similarly, models can optimize diuretic therapy by simulating the effect of furosemide on preload and renal function in the context of the patient’s Frank‑Starling curve.

Optimizing Device Therapy

Cardiac resynchronization therapy (CRT) is a mainstay for HFrEF patients with wide QRS. However, about 30% of patients do not respond. Electromechanical models can predict CRT response by simulating the effect of pacing at different sites. A patient‑specific model built from MRI and ECG data can identify the optimal left ventricular lead position that minimizes mechanical dyssynchrony and maximizes stroke work. Clinical trials such as the “Virtual CRT” study have shown that model‑guided lead placement improves response rates. Beyond CRT, models assist in programming implantable cardioverter‑defibrillators (ICDs): they can simulate arrhythmia induction and termination, helping to tailor detection algorithms and reduce inappropriate shocks.

Predicting Disease Progression and Risk Stratification

Heart failure is a progressive syndrome. Models that incorporate patient‑specific parameters can simulate the course of the disease over months or years. For instance, a model might incorporate the gradual increase in left ventricular mass (hypertrophy) and the decline in contractility seen in hypertensive heart disease. By running thousands of virtual patients, researchers can identify the key parameters that drive decompensation. Clinically, such models can stratify risk: a patient whose model shows a steep decline in stroke volume with small increases in afterload may be at higher risk for acute decompensation during a hypertensive crisis. This “digital twin” concept—a continuously updated model of the patient—holds promise for early warning and preemptive intervention.

Guiding Mechanical Circulatory Support

For advanced heart failure, ventricular assist devices (VADs) are used as a bridge to transplantation or as destination therapy. However, VAD settings must be adjusted to balance left ventricular unloading with adequate systemic perfusion. Models of the assisted circulation can predict the effect of pump speed on left ventricular volumes, septal position, and right ventricular function. A model that includes both ventricles and the VAD can help clinicians choose the optimal speed that avoids left ventricular suction (collapse) or right heart failure. Such simulations reduce the need for invasive ramp studies and may lead to better long‑term outcomes.

Challenges and Limitations

Despite their promise, physiological cardiac models face several hurdles before widespread clinical use. First, data requirements are high: building a patient‑specific model often requires high‑resolution imaging (MRI, CT), invasive pressure measurements, or detailed electrophysiological data. Many heart failure patients have contraindications to MRI (e.g., ICDs) or cannot tolerate lengthy scanning. Second, model calibration and validation remain challenging. A model that fits one set of data may not generalize to another population or clinical scenario. Rigorous validation against large, prospective clinical datasets is needed—a process that is expensive and time‑consuming. Third, computational cost remains a barrier for 3‑D electromechanical models, which can take hours to simulate a single beat. Real‑time or near‑real‑time simulation is needed for clinical decision‑making. Advances in reduced‑order modeling and GPU‑accelerated computing are addressing this, but the gap persists. Fourth, uncertainty and variability in model parameters (e.g., tissue stiffness, ion channel kinetics) must be quantified. Probabilistic modeling approaches, such as Bayesian calibration, are being developed to provide predictions with confidence intervals. Finally, regulatory and clinical acceptance requires evidence that model‑guided decisions improve outcomes compared to standard care. Randomized controlled trials of model‑based interventions are still rare.

Future Directions: From Simulation to Clinical Integration

The next decade will likely see physiological modeling become an integral part of heart failure care, driven by several converging trends.

Artificial Intelligence and Machine Learning

Machine learning (ML) can accelerate model building by automatically extracting parameters from imaging and signals. For example, deep learning can segment the left ventricle from echocardiograms and estimate chamber volumes in seconds. ML can also identify the most informative parameters for a given patient, reducing model complexity. At the same time, physics‑informed neural networks (PINNs) are emerging as a method to directly learn the solution of the governing equations from sparse data, potentially bypassing traditional model calibration altogether. Combining ML with mechanistic models (hybrid modeling) may yield the best of both worlds: the interpretability of physiology and the flexibility of data‑driven methods.

Digital Twins of the Heart

A digital twin is a virtual representation of a patient’s heart that is continuously updated with real‑world data from wearables, implantable monitors, and electronic health records. For heart failure, a digital twin could simulate daily variations in fluid status, heart rate, and blood pressure, then alert the clinician when the model predicts impending decompensation. Projects such as the European “DigiTwin” and the NIH‑funded “Computational Heart” are working toward this vision. Early prototypes have demonstrated the ability to personalize CRT settings and predict acute hemodynamic response to vasoactive drugs.

Integration with Wearable and Implantable Sensors

Modern pacemakers and defibrillators can continuously measure intrathoracic impedance (a proxy for fluid overload), heart rate variability, and activity level. When these data streams are fed into a cardiac model, the model can adjust its predictions in real time. For instance, a decrease in impedance combined with an increase in resting heart rate might trigger a model simulation that suggests incipient pulmonary congestion, prompting a diuretic adjustment. Such closed‑loop systems are already being tested in pilot studies for managing chronic heart failure.

Clinical Trials and Regulatory Pathways

For models to be adopted, they must demonstrate clinical utility. The US Food and Drug Administration (FDA) has begun to consider in silico evidence as part of regulatory submissions, particularly for device development. The “Medical Device Development Tools” (MDDT) program allows qualified computational models to be used as surrogate endpoints in clinical trials. In 2023, the FDA qualified a computer model of the cardiovascular system for use in evaluating new heart failure drugs. This regulatory acceptance will encourage wider use. At the same time, initiatives like the “Virtual Physiological Human” aim to create standards for model verification, validation, and sharing, reducing duplication and improving reproducibility.

Expanding to HFpEF and Other Subtypes

Most modeling work has focused on HFrEF, but HFpEF represents half of all heart failure cases and has few effective treatments. Modeling HFpEF is more challenging because it involves subtle diastolic dysfunction, often combined with comorbidities such as obesity, hypertension, and atrial fibrillation. New models that incorporate left atrial function, pulmonary vein hemodynamics, and the pericardial constraint are being developed. For example, models that simulate the ventricular‑vascular coupling during exercise can reproduce the exaggerated rise in filling pressures that characterizes HFpEF. Such models may help identify which patients benefit from specific therapies (e.g., sodium‑glucose cotransporter‑2 inhibitors or new myosin‑activating drugs).

Conclusion

Physiological modeling of the cardiac cycle has matured from a research curiosity into a powerful tool for understanding and managing heart failure. By capturing the complex interplay of electrical, mechanical, and hemodynamic factors, models can personalize therapy, predict outcomes, and guide device and drug development. While challenges remain—data availability, validation, computational burden—the field is now moving from proof‑of‑concept to clinical integration. As artificial intelligence, digital twins, and regulatory frameworks evolve, physiological modeling is poised to become a standard component of precision cardiology for heart failure.

Further reading: For a comprehensive review of cardiac modeling approaches, see the Nature Reviews Cardiology article on cardiac electromechanical models. The American Heart Association provides updated heart failure statistics at their 2024 statistics update. For insights into digital twin technology in cardiology, see the Digital Twin in Cardiovasculature review. Additional resources on lumped parameter modeling for heart failure can be found in the PMC article on closed‑loop circulation models.